A long-lasting universal flu vaccine
For decades, researchers have been doggedly pursuing a universal flu vaccine--one that would protect against the evolving influenza virus for years rather than just a single season--with little success. The bug mutates so quickly that a new vaccine must be specially formulated each year. But a relatively new strategy, targeting a rarely seen portion of the virus, is now showing some success.
A novel vaccine developed by microbiologist Peter Palese and collaborators at Mount Sinai School of Medicine in New York showed protective effects in rodents against three different flu strains, with protection ranging from mild (against hemagglutinin 1, such as that of the H1N1 or "swine" flu) to middling (against the avian flu H5 subtype) to absolute (against the common H3 flu subtype). While the results are far from perfect, the proof-of-principle demonstrates the potential for a universal flu vaccine.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- 3 Traits Personality Assessments Can't Reveal
- Carondelet to Pay $35M to Settle Fraud Allegations
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Cleveland Clinic Partners with North Shore-LIJ for Heart Care